Research progress of induction immunotherapy before radiotherapy in unresectable stage Ⅲ non-small cell lung cancer
10.12354/j.issn.1000-8179.2024.20240257
- VernacularTitle:放疗前诱导免疫治疗在不可切除Ⅲ期非小细胞肺癌中的研究进展
- Author:
Zeng LI
1
;
Zhang HONGPAN
;
Ma DAIYUAN
Author Information
1. 川北医学院,川北医学院附属医院肿瘤科(四川省南充市 637000)
- Keywords:
induction immunotherapy;
non-small cell lung cancer(NSCLC);
research progress
- From:
Chinese Journal of Clinical Oncology
2024;51(5):264-268
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related deaths worldwide,and non-small cell lung cancer(NSCLC)is the most common type.Because more than one-third of NSCLC patients are diagnosed at stage Ⅲ,most of these tumors are unresectable.Chemoradiother-apy(CRT)is the standard treatment for unresectable stage Ⅲ NSCLC;however,its curative efficacy is poor.Compared with simple CRT,the survival rate of patients with unresectable stage Ⅲ NSCLC following consolidated immunotherapy after CRT has significantly improved ow-ing to the emergence of immune checkpoint inhibitors.However,a subset of patients do not benefit from consolidated immunotherapy.Based on the effectiveness of induction immunotherapy in resectable stage Ⅲ NSCLC,studies have been conducted to extend its application in unresectable stage Ⅲ NSCLC.This article reviews the mechanism of action,recent advancements in clinical research,and cycle of induc-tion immunotherapy before radiotherapy in unresectable stage Ⅲ NSCLC to provide a reference for clinical treatment of unresectable stageⅢ NSCLC.
